Intentar ORO - Gratis

Covid-19 Linked Maladies Startling Researchers

BioSpectrum Asia

|

November 2020

Although millions of people have recovered from the coronavirus worldwide, beating the initial sickness appears to be the first of many battles for those who have survived. The list of gnawing maladies associated with COVID-19, such as heart diseases, liver injuries, brain damage, anosmia etc., is surely of a huge concern for the world.

- Pooja Yadav

Covid-19 Linked Maladies Startling Researchers

COVID-19 has taken a significant toll on people all across the world. It has not only upended lives in huge proportions but has also left deadly after-effects among patients. According to scientists, COVID-19 can have long-term consequences on the human body, which can be very dangerous.

The problems seen in recovered patients have alarmed many scientists, doctors and researchers as it could lead to severe brain, heart, kidney or liver disorders. Other than affecting the main parts of the body, the list of lingering maladies from COVID-19 also involves problems like fatigue, racing heartbeat, shortness of breath, achy joints, foggy thinking, persistent loss of sense of smell, and mental illness.

Researchers from all over Asia, in Singapore, China, Hong Kong, India, Japan and Taiwan have come up with many studies showing severe effects of COVID-19 on the heart, liver, kidney and brain in recovered patients.

Impact on heart

Studies have shown that COVID-19 recovered patients in Singapore have died from ischaemic heart disease. It has been confirmed and proven by many scientists now that COVID-19 can impact the heart health in more ways than one. In many ways, the acute inflammatory response fueled by the virus can also complicate matters. Acute inflammation could obstruct arteries, cause blood clots, which contribute to reduced heart function. It can also so happen that people with rapid heartbeats could observe heart muscle weakening, which can cause damage to the heart.

MÁS HISTORIAS DE BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

Collaborative R&D: Partnerships shaping the future of biopharma

Biotechs and pharma companies face rising costs of drug development, depleting R&D pipelines and diminishing returns on investment. By joining forces and exploring collaborative R&D partnerships it is possible to overcome these challenges. In addition to sharing risks, they share the potential rewards when their assets move further into clinical development or come to the market.

time to read

2 mins

BioSpectrum Asia Sep 2025

BioSpectrum Asia

BioSpectrum Asia

Quantum Computing: Future of diagnostics is being coded today

A silent revolution is being built at the intersection of biology and quantum physics. After decades of pushing the boundaries of diagnostics with advanced imaging and AI, we are now approaching a hard computational wall. For complex conditions like Alzheimer's, Parkinson's, and many cancers, the interacting variables of genomics, proteomics, and real-world patient data are simply too vast for classical computers to master. This limitation caps the ability to move from merely spotting correlations to uncovering true causation. Unlike traditional AI, quantum computing can simulate underlying physical systems to derive precise solutions. The transition from correlational analysis to causal simulation will enable a more valuable and advanced frontier in diagnostics.

time to read

4 mins

BioSpectrum Asia Sep 2025

BioSpectrum Asia

First Pacific woman to serve as public health director in NZ

The Ministry of Health in New Zealand (NZ) has appointed Dr Corina Grey as the new Director of Public Health this year, a landmark appointment for Pacific leadership.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

Bio-Rad appoints Rajat Mehta as Executive Vice President of Global Commercial Operations

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, has announced the appointment of Rajat Mehta as its new Executive Vice President, Global Commercial Operations, effective August 4, 2025.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

BioSpectrum Asia

Hugel launches botulinum toxin Letybo in Malaysia

South Korea-based Hugel Inc., a leading global medical aesthetics company, has officially launched its botulinum toxin product Letybo in Malaysia - an emerging market for medical aesthetics in Southeast Asia.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

BioSpectrum Asia

Australia designs smart wound monitor to improve chronic infection care

Researchers from Australia's RMIT University have developed a wearable wound monitoring device with integrated sensors that could reduce infection risks by minimising the need for frequent physical contact.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

Revvity unveils innovative reagent technology to accelerate therapeutics development

US-based Revvity, Inc. has announced the launch of pHSense reagents, a powerful technology designed to advance internalisation studies in drug discovery.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

BioSpectrum Asia

Sanofi acquires next-gen vaccine biotech Vicebio for $1.6 B

Vicebio, a biopharmaceutical company with operations in Australia, UK and Belgium, has entered an exclusive, definitive agreement to be acquired by Sanofi.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

HOSMAC signs MoU with Gulf Medical University to strengthen healthcare education

HOSMAC, Asia's leading hospital planning, design, and management consultancy, has signed a Memorandum of Understanding (MoU) with Gulf Medical University (GMU), Ajman, UAE, to serve as an industry partner.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

Jessica Cowden takes charge as Deputy Director General of CARE unit at IVI

Dr Jessica Cowden has been appointed Deputy Director General of the Clinical, Assessment, Regulatory, Evaluation (CARE) unit at South Korea-headquartered International Vaccine Institute (IVI). She will continue to be based at IVI's Europe Regional Office in Stockholm, Sweden.

time to read

1 min

BioSpectrum Asia Sep 2025

Translate

Share

-
+

Change font size